Myelofibrosis News

Impact Biomedicines to resurrect abandoned myelofibrosis drug - The Pharma Letter (blog)



Impact Biomedicines to resurrect abandoned myelofibrosis drug 
The Pharma Letter (blog)
US biotech start-up Impact Biomedicines announced its launch to pioneer the development of life-changing treatments for patients with myeloproliferative neoplasms, a rare form of blood cancer, and other cancers. The company's pipeline is centered ...

 


Impact Biomedicines Raises $22M to Bring Fedratinib to Myelofibrosis Patients - Drug Discovery & Development



Drug Discovery & Development
 
Impact Biomedicines Raises $22M to Bring Fedratinib to Myelofibrosis Patients 
Drug Discovery & Development
The Company's pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). In conjunction with this ...

 


Momelotinib vs Ruxolitinib for Myelofibrosis: Phase 3 Trial Yields Mixed Results - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Momelotinib vs Ruxolitinib for Myelofibrosis: Phase 3 Trial Yields Mixed Results 
Cancer Therapy Advisor
Among patients with myelofibrosis, momelotinib is inferior to ruxolitinib for total symptom score (TSS) reduction, but not for spleen-volume reduction, according to an article published in the Journal of Clinical Oncology.1. Myelofibrosis is a ...

 


Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib - Endpoints News



Endpoints News
 
Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib 
Endpoints News
Seven years ago, Sanofi scooped up a biotech called TargeGen in a $635 million deal, bagging a mid-stage JAK2 myelofibrosis drug ? then dubbed TG 101348 ? that had gathered promising early-stage human data. Hood, the former research chief at ...
Big Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It Forbes
Impact bags $22M to save ex-Sanofi drug from trial limbo FierceBiotech

all 4 news articles » 


Startup Impact Biomedicines Raises $22M to Bring Fedratinib to Myelofibrosis Patients - Business Wire (press release)



Startup Impact Biomedicines Raises $22M to Bring Fedratinib to Myelofibrosis Patients 
Business Wire (press release)
The Company's pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). In conjunction with this ...
Impact Biomedicines Raises $22M For Treating Myelofibrosis socalTech.com

all 2 news articles » 


Study Administers IMG-7289 to First Patients with Myelofibrosis - Rare Disease Report



Rare Disease Report
 
Study Administers IMG-7289 to First Patients with Myelofibrosis 
Rare Disease Report
The clinical trial (NCT03136185) is being conducted at multiple locations in Australia, and is expected to evaluate the safety, pharmacokinetics, and pharmacodynamics of the orally administered IMG-7289 in patients with high-risk myelofibrosis ages 18 ...

 


Rare Disease ReportŪ to Cover Myelofibrosis Awareness Day - Business Wire (press release)



Rare Disease ReportŪ to Cover Myelofibrosis Awareness Day 
Business Wire (press release)
In observance of Myelofibrosis Awareness Day and to raise awareness and advance research for myelofibrosis, Rare Disease Report will be sharing content on its website and social media accounts featuring the latest information pertaining to ...

and more » 


Risk Factors in Myelofibrosis Linked With Poor Outcome After Splenectomy - Cancer Network



Risk Factors in Myelofibrosis Linked With Poor Outcome After Splenectomy 
Cancer Network
Survival of patients with myelofibrosis (MF) who undergo splenectomy is adversely affected by older age, the need for transfusion, and leukocyte and circulating blast cell counts, according to a new analysis. The findings, and a score developed to ...

 


New Research Report Offers Analsysis on Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017 - Digital Journal



New Research Report Offers Analsysis on Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017 
Digital Journal
The report is a comprehensive guide on the Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review and provides comprehensive information on the development of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology). The report offers ...

 


Imago BioSciences Doses First Patients in Phase 1/2 Study of IMG-7289 in Myelofibrosis - PR Newswire (press release)



Imago BioSciences Doses First Patients in Phase 1/2 Study of IMG-7289 in Myelofibrosis 
PR Newswire (press release)
"By targeting an enzyme specifically regulating myeloid cell gene transcription, IMG-7289 has significant disease-modifying activities in multiple non-clinical models of myelofibrosis and thus offers the possibility to influence the natural history of ...

and more »